{"links":{"html":"https://www.erudio.com/reports/star-trec-nct02945566","json":"https://www.erudio.com/reports/star-trec-nct02945566.json","markdown":"https://www.erudio.com/reports/star-trec-nct02945566.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"star-trec-02945566"}},"request":"https://www.erudio.com/contact?report=star-trec-02945566"},"offer":{"cited_commentary_sources":79,"verified_hcp_statements":303,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":40,"optional":true,"price_per_verified_person_usd":15,"price_usd":600,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"star-trec-nct02945566"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=star-trec-02945566","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/star-trec-nct02945566","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T11:41:26.298489Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Phase II (Feasibility study) Primary Outcome: Recruitment Rate"},{"claim_count":43,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":19,"title":"Primary endpoint: Phase III Primary Outcome: Organ Preservation"},{"claim_count":24,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":14,"title":"Secondary endpoints"},{"claim_count":17,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":13,"title":"Population and setting"},{"claim_count":40,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":25,"title":"The comparison"},{"claim_count":21,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":11,"title":"Safety and tolerability"},{"claim_count":20,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":14,"title":"Design and conduct"},{"claim_count":15,"coverage":"discussed","id":"A1","source_count":11,"title":"Patient-reported function and reasons to avoid competing treatments"},{"claim_count":18,"coverage":"discussed","id":"A2","source_count":7,"title":"Mesorectal-only fields, anal-canal sparing and planning quality"},{"claim_count":13,"coverage":"discussed","id":"A3","source_count":4,"title":"Dose escalation and brachytherapy as organ-preservation alternatives"},{"claim_count":10,"coverage":"discussed","id":"A4","source_count":5,"title":"Travel, radiation capacity, economics and sequence-dependent choices"},{"claim_count":12,"coverage":"discussed","id":"A5","source_count":7,"title":"Insufficient response, systemic treatment and biomarker-guidance questions"},{"claim_count":16,"coverage":"discussed","id":"A6","source_count":1,"title":"Preoperative versus definitive dose-response and radiobiological explanations"},{"claim_count":50,"coverage":"discussed","id":"A7","source_count":27,"title":"Guideline expectations, adoption, collaboration and evidence thresholds"},{"claim_count":40,"coverage":"discussed","id":"A8","source_count":19,"title":"Patient experience, public communication and support implications"}],"counts":{"cited_sources":84,"claims_by_expression_type":{"comparison":22,"experience":12,"interpretation":60,"opinion":83,"primary_context":19,"question":15,"restatement":32,"uncertainty":25,"unspecified":35},"claims_by_kind":{"interpretation":3,"objective_result":2,"protocol_statement":6,"publication_statement":61,"source_observation":231},"clinician_statements":75,"evidence_units":246,"findings":11,"organisational_accounts":11,"people_cited":56,"people_identity_verified":40,"people_total":58,"screened_sources":160,"verified_claims":303},"findings_index":[{"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":2,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":5,"passages":12,"sources":8,"sources_by_kind":{"commentary":4,"media":3,"registry":1}},"title":"The early long-course advantage is not read as proof of equivalent cancer control"},{"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":11},"has_counterview":true,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":4,"passages":12,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Short-course criticism reaches treatment and trial-participation decisions, but dissent is setting-specific"},{"id":"F3","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":9},"has_counterview":true,"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":8,"passages":12,"sources":8,"sources_by_kind":{"commentary":6,"media":1,"publication":1}},"title":"Selection, response assessment and capacity for surveillance define the opportunity"},{"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":3,"restated":2,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":4,"passages":6,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Avoiding surgery is not a substitute for knowing pelvic function and treatment harms"},{"id":"F5","structure":{"claims":13,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":3,"views":6},"has_counterview":true,"limitations":3,"links":{"context":1,"support":13},"ma_question":true,"named_voices":5,"passages":10,"sources":5,"sources_by_kind":{"commentary":2,"media":2,"publication":1}},"title":"Mesorectal-only fields are themselves a perceived innovation, with clinical and planning caveats"},{"id":"F6","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":0,"views":4},"has_counterview":true,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":5,"passages":7,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Convenience and access sustain interest in shorter treatment, but cost and sequencing are contested"},{"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":2,"questions":1,"restated":2,"views":5},"has_counterview":true,"limitations":3,"links":{"context":1,"support":13},"ma_question":true,"named_voices":5,"passages":13,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Dose escalation and contact brachytherapy attract strong support, qualified by size, evidence interpretation and access"},{"id":"F8","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":0,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":8,"passages":11,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Alternative regimens and added immunotherapy remain questions rather than established improvements"},{"id":"F9","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":10,"views":4},"has_counterview":true,"limitations":3,"links":{"context":4,"support":15},"ma_question":true,"named_voices":5,"passages":13,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Preoperative schedule evidence is not treated as a complete answer for definitive organ preservation"},{"id":"F10","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":2,"questions":3,"restated":4,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":17},"ma_question":true,"named_voices":9,"passages":15,"sources":12,"sources_by_kind":{"commentary":9,"media":1,"publication":1,"registry":1}},"title":"Patient-preference design and recruitment earn praise, while enthusiasm may outrun maturity"},{"id":"F11","structure":{"claims":20,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":9,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":20},"ma_question":true,"named_voices":5,"passages":12,"sources":9,"sources_by_kind":{"commentary":5,"media":4}},"title":"Patient stories give organ preservation meaning, but public descriptions can overgeneralize"}],"medical_affairs_question":"What evidence and service capability are needed to discuss selective organ preservation confidently without overstating long-term safety or dismissing access-dependent alternatives?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Early preservation is not yet a durable oncologic assurance"},{"id":"section-2","level":2,"title":"The short-course dispute concerns evidence thresholds and treatment intent"},{"id":"section-3","level":2,"title":"Selection and surveillance are part of the treatment proposition"},{"id":"section-4","level":2,"title":"Function and harms determine whether preservation is worthwhile"},{"id":"section-5","level":2,"title":"Reduced fields are a separate clinical and implementation issue"},{"id":"section-6","level":2,"title":"Access and treatment sequence keep alternative regimens relevant"},{"id":"section-7","level":2,"title":"Brachytherapy enthusiasm needs outcome, size and capability distinctions"},{"id":"section-8","level":2,"title":"Added agents and alternative strategies remain investigational next steps"},{"id":"section-9","level":2,"title":"Radiobiology explains why surgical and nonsurgical evidence may differ"},{"id":"section-10","level":2,"title":"Design praise, feasibility and anticipated adoption are different from confirmed benefit"},{"id":"section-11","level":2,"title":"Patient meaning is powerful but anecdotal communication needs boundaries"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F10","shared_claims":3}],"id":"T1","label":"Primary endpoint: Phase II (Feasibility study) Primary Outcome: Recruitment Rate"},{"findings":[{"id":"F1","shared_claims":10},{"id":"F3","shared_claims":4},{"id":"F8","shared_claims":1},{"id":"F10","shared_claims":3},{"id":"F11","shared_claims":1}],"id":"T2","label":"Primary endpoint: Phase III Primary Outcome: Organ Preservation"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":2},{"id":"F8","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":8},{"id":"F4","shared_claims":1},{"id":"F11","shared_claims":3}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":4},{"id":"F8","shared_claims":2},{"id":"F10","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":3}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F10","shared_claims":9}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T11:41:26.298489Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T11:55:42Z","record_hash":"6c4ed830296cbadf4ea94b5180eeaaceab8bba759871f510fa16cb0568507816","release_hash":"a479f9459d32fb125ae569431eba4a61fc2b9834d6b3b3d6ac60e763ee282234","report_id":"erudio-nct02945566","run_id":"eafe510b-c5ce-4f52-ae27-d49f2437740c","schema_version":"5.0","slug":"star-trec-02945566","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on STAR-TREC in the sources reviewed for this edition leads to one open question: What evidence and service capability are needed to discuss selective organ preservation confidently without overstating long-term safety or dismissing access-dependent alternatives? Its leading findings: (1) the early long-course advantage is not read as proof of equivalent cancer control. (2) short-course criticism reaches treatment and trial-participation decisions, but dissent is setting-specific. (3) selection, response assessment and capacity for surveillance define the opportunity. 8 more findings follow. 160 sources screened, 84 cited; not all HCPs or all public discussion.","meta_description":"160 sources screened · 303 verified statements (75 from clinicians verified by NPI or staff page) from 84 sources · 11 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-31T11:55:42Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":160},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a question about evidence for low alpha/beta in rectal cancer and its possible implications for radiotherapy fractionation.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","94 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The report describes the sources reviewed for this edition, not all HCPs or all public discussion; discussion frequency and source numbers cannot establish clinician consensus.","A complete text was unavailable for one review of local versus radical surgery. Its conclusions should not be treated as a comprehensive account of every underlying study.","The directly included results paper concerns radiotherapy planning. Early clinical comparisons are conveyed through attributed commentary and a linked article summary; those sources do not establish mature 30-month clinical outcomes.","Individual opinions, relayed presentations, institutional communication and patient anecdotes are different kinds of evidence. Reposting does not establish independent endorsement.","Clinical roles are unstated or unconfirmed for several named authors. Descriptions of credentials, trial participation or leadership remain attributed to their sources, and do not increase the evidentiary weight of a view.","Several video passages cannot be assigned to a named speaker from the spoken material. Captions, publisher descriptions and a named person elsewhere in the recording do not resolve those passages.","Endpoint and population labels are inconsistent in some comments, including a speaker's 18% and approximately 25% statements and another speaker's locally advanced description and numerical characterization. They are preserved as statements, not silently corrected.","Comparisons involving TREC, OPERA, WW2, NEO, TOWARd, RAPIDO and retrospective series retain their own settings and uncertainties. They are not STAR-TREC results or proof that their populations and regimens are interchangeable.","Post dates and recruitment updates do not establish readout dates, changes of mind, current practice prevalence or confirmed guideline change."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":1,"publication":4,"registry":1,"regulatory":0,"x_thread":70,"x_video":4,"youtube":2},"by_evidence_role":{"commentary":79,"context":2,"methods":2,"results":1},"count":84,"evidence_window":{"end":"2026-10-23","start":"2016-05-13"},"retrieval_snapshot":"2026-10-31T10:05:32.343490Z","timeline":[{"count":1,"week":"2016-W19"},{"count":1,"week":"2016-W24"},{"count":1,"week":"2018-W01"},{"count":1,"week":"2018-W27"},{"count":1,"week":"2019-W17"},{"count":2,"week":"2019-W23"},{"count":1,"week":"2019-W27"},{"count":1,"week":"2019-W33"},{"count":1,"week":"2019-W46"},{"count":1,"week":"2020-W03"},{"count":1,"week":"2020-W07"},{"count":1,"week":"2020-W23"},{"count":1,"week":"2020-W50"},{"count":1,"week":"2021-W01"},{"count":1,"week":"2021-W29"},{"count":1,"week":"2021-W30"},{"count":1,"week":"2021-W41"},{"count":1,"week":"2021-W49"},{"count":2,"week":"2022-W14"},{"count":1,"week":"2022-W21"},{"count":3,"week":"2022-W22"},{"count":7,"week":"2022-W23"},{"count":1,"week":"2022-W25"},{"count":1,"week":"2022-W38"},{"count":1,"week":"2022-W42"},{"count":1,"week":"2022-W44"},{"count":1,"week":"2023-W03"},{"count":1,"week":"2023-W05"},{"count":2,"week":"2023-W06"},{"count":2,"week":"2023-W07"},{"count":1,"week":"2023-W10"},{"count":1,"week":"2023-W19"},{"count":1,"week":"2023-W45"},{"count":2,"week":"2023-W46"},{"count":2,"week":"2023-W50"},{"count":2,"week":"2024-W17"},{"count":1,"week":"2024-W19"},{"count":6,"week":"2025-W18"},{"count":2,"week":"2025-W19"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2026-W21"},{"count":11,"week":"2026-W35"},{"count":2,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":3,"week":"2026-W42"},{"count":2,"week":"2026-W43"}],"undated_sources":5},"quote_policies":[{"id":"clinicaltrials:NCT02945566:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02945566:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:29288190","quote_policy":"short_quote_link_out"},{"id":"pubmed:32070386","quote_policy":"short_quote_link_out"},{"id":"pubmed:32095545","quote_policy":"short_quote_link_out"},{"id":"pubmed:37310167","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47nm5qperrpmcqdmzxt3qgec-3mu4xtscijc2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hs3t3iduvwk6uw3zbititzs3-3mtt6zioggk22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-nryb43ydciicbfogfiqmw5dz-3mtvriaz3l225","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-q26bqdudtrrgpykpgpemojm3-3mtsverfljk2k","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-q26bqdudtrrgpykpgpemojm3-3mtvl3b2r3c2m","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-wdt7kda3h45gblehcgvom3u4-3myy22phzc22y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xfpemsycdfthtazftb7ylayy-3lodly25rm22a","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7497743435156660224","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:1d78b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1013853579185139713:c64d58ba-4156-4419-a8b9-148e6fca421d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1035076486322167809:34b35d0a-c8e0-4cab-af6a-7486633d0f07","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1121712705390424064:652a0b46-de4e-4db3-ba0f-3aa4ded61054","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1135527178584711173:ed1bfb74-6cf3-4919-b8a8-ca16b7564e1f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1137027322190671872:e7dabbcf-1ce0-4aab-899a-54e83351348c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1146333950425686016:fe7d7a11-67ea-4abb-8f35-885330906c8d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1161528373816041474:5b5520e2-f001-460c-ac7d-9ac490b3b2f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1182228113427718147:44777bb6-5e62-4282-bfca-456f198821c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1194623698562498560:12a3cb91-d442-4763-b736-4e195ef63706","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1219031188259639299:0b1d7229-5277-4710-99eb-e20c7ae8c81f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1228660056444604416:a3964054-134a-4123-8a4b-d3e8f526bce9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1228686846688886786:8a162375-340f-4646-85da-e098880d3100","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1228687910771265537:1341f99e-3c5b-44cf-9b52-833010528093","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1230553801628635137:a9597c70-cabb-4b03-8cf6-440f53dd3e2a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1268689165127827456:ca46a4be-7bac-47f8-b2d3-64e14400df7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1337400997782708234:02764474-f92c-4f9d-a029-69d3121ba5d1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1337476998587936768:64898a22-3478-4d2b-869d-eb9d81a13f4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1337725303502876672:9a9fb037-5097-42c0-9688-df14bc0a2ae1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1346042917396373508:eaa21a7a-2a92-4c9f-b59b-028d930d34f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1350469613801369604:6b90846b-3cca-40a5-96f6-a77fdc756e41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1417907598486028288:6aa7bdbe-7ed7-4fd2-bfa8-0adc411fa2c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1421074026395537417:7027b38a-5a28-4199-8079-5817d4ce4328","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1449147410429718540:747fe8bc-6c65-4d02-9dd6-5b3db3bab0a6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1469407265920802825:99130e29-4888-4f2b-b97c-62ec4c0a462a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1489397118078832640:c1682366-ab77-4e44-a906-a35fa2c57efc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1506949207038562311:6e40352e-534b-4df9-8fe0-5b7a2ca173ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1511251508821643264:6a40bf0d-46e5-4170-89b3-dcc200e89226","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1512136784444014593:41a8a4a6-5475-4ee1-8507-0d7fe89cefc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1525859583595466752:e50dcc76-d958-4f80-9f04-d4ca2e73ba0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1527611076434612224:3408a777-90f8-4dd9-8825-9485f05e7586","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1528821366379757572:3fd0c792-2f14-424e-8ac5-28d29521806f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1530123526748921858:875c0f11-57ee-4ed8-a43d-e1c770862ce8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1531665392456060928:97fd80aa-6ddd-4039-a8b5-15a930724b90","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1531980617931440128:4a298bb4-fec9-4336-806c-77f906ea152f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532675278501208067:5cb19908-5ee4-4449-93aa-c2b4c203d326","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533751301900746753:bd2dc6e7-de6e-4b2b-8b0b-75eca269064d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533828594107129856:f151caef-d9bd-4450-a73a-18bb74b75125","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533829163446149121:e3881919-700e-4abb-a340-38d42e384d52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533831386049675264:05d1c110-6534-4110-924c-04848f2ddedd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533831625519284225:134404ca-31c1-4e54-a9c3-eece8c527b7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533832032022941696:35e2a25f-57ec-4cfd-8fd1-765d0e6ccc64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533832241750622211:a4ce72cf-7d9e-48c3-afd5-6015bfd724ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533834638279442433:38e69f34-7a2b-4b2c-b238-1e5c874941dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533835728311812099:17ed01cb-5ee1-4e76-90c4-ee1247b4c47e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533837476040695808:2706c4b5-32b3-4727-bbc9-6cc3588d0334","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1534043748321087488:ca574154-6095-4d6f-adf5-83b5ca51cac7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1534188060296073217:bd8bc0fe-1e56-4136-ac85-ced6ac044233","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1540133062306054144:c7302438-c61c-4241-b94a-ef748c49b893","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1560409165457108992:551900d7-6b60-4e32-be2e-5be0e43e7ff6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1572521152375058432:d9d836ea-3123-441b-86cf-b29fe8501409","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1583093155276017666:cb3bdfeb-f4a9-4630-b30a-8550656c6e8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1583118633576075265:e7e5c79c-e1cb-4d38-970d-3cc99959aa11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1587466423160504321:e229c598-9549-4781-947d-b342298d6f9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1614245411098697730:5264de54-7b2c-44b8-9d30-13ff8e96fbb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1616818142407454720:b957e904-d7c6-41c8-b5d2-5bf81368eb8d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1616888615552049152:9556cd9e-5550-490f-90a7-0e4f4c997ff5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1621834741459701760:ce54caac-fb44-43b3-bad3-7c300c30dd31","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1622987950354055168:eaf06920-3e69-4e29-bcfe-a4325cc5ca6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1624122238411603988:bfbc4969-569f-4bd0-bf8c-66b23d5bd284","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1626393744164671490:9f8975fc-6334-4dfa-b638-176396c15de0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1626399783727558656:38ae9d92-45bb-478a-a2a2-e3eb55e58668","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1634811260167487488:771987cc-02ae-4514-bff3-bde77f344b2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1657404373213798400:174b079c-b442-4b4e-a9c6-97dd993af1dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1657659048047566851:86b30231-1c9d-4ed3-a49e-7ddcf24a66d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1721601842864345207:59e61fae-f09d-4655-94d7-31fd07fa003a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1724558904586105203:a07985bc-8cf5-487e-8eac-a624c48e2ce8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725217328915153398:dc6bed86-0963-4add-8602-239a60b148fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1735691153213673783:5138794d-6b47-49d3-a761-f717d2d14a9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1762562424774029621:84d3cea4-7d10-4a59-9ef9-16165eb67873","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783749075092865255:fc069f24-ae9a-434d-a731-bf225499c5f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783872323210064360:5788e471-4d77-42d1-bce1-2236a27004d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1787766768200495124:c70f92bb-655f-4cbb-8823-6e57cdfdf413","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916385719980826680:4676315e-67e2-4d12-8f67-95d35e748f52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1917839627739881686:1b7aa3f0-5b50-494c-91d9-bc68ace5ef6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918969241748844603:44c69ed2-97a2-4fe4-a482-016633f40406","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918969345213931728:7a3c41e6-995c-4635-9b8c-d0edc93e4afa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918978499404021984:ff723149-9878-464f-ae97-5b0804e123bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918992272575586629:d483e595-4825-467b-a2f2-a7fd1c43c94b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918994270951768413:af28e68c-8685-4138-b5e2-05c8af282b7a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918999950152929356:0e4727a1-9ec5-42bf-9fe9-3f35ef9a5ec6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919031367221772692:c1d5b338-a452-4e06-9ac8-52a9e266c1db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919031919674621956:57d75ff8-efdf-4194-90f3-7721a200141f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919159009723973819:7233c500-6fb7-41f1-8d6b-5f77e887b1b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1920058008861585789:a096818c-fc35-40ab-aa29-88a98a7eea19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1920366957682913396:7551b10d-4072-44df-a1ed-5727dc05ff93","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928753376222744783:df8a833b-1794-4644-8e23-692b29b3d96e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1966073826116096235:feefd88c-1afa-4a8f-9422-814474bfd3ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1966085159624602033:c9a52888-e703-4675-93a0-ddff851fe228","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1994696359132422389:6b2a8289-c2ba-46d5-b9f3-9471a109fa0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056316161151709236:d68ca984-6008-4576-b66d-ee22c806ce86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056645716185890920:b8d6d0dd-bf42-4d3a-8972-afc643cd2c12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091777451412406481:f8455944-b2d6-432e-96b9-63a6f4cc5a3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091805326114796010:69be8d3e-03a8-4e77-94c0-2e6331cca200","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091849722717769884:450e75c3-576f-476c-bd0c-a23686d1dc75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091889608308998407:1a0ae8c4-9bcf-4994-9c4a-d68d8f94575d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091904486906237309:4e571810-568c-49e8-ac39-a1a4c05455d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091908337545654606:fc3e0f30-7b4f-43fd-bc10-16c2c781ee67","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091914896686428438:a0cf3dbf-5960-4acb-8a9c-3f138de39f44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091921453155508557:e6cf48f9-f1c9-4175-b549-75c14ab81b74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091963803764244542:e508496b-615f-452c-a138-9a93f4e7a857","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091971974780404006:f09a309d-30d9-4f8d-b8f3-c946293d0c48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091978598555193431:326a378a-6098-454e-9ca0-c0edbacef46d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092020388666528074:598d5824-7823-4342-9521-888786c719b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092024383543886075:47bbab67-efcb-4ef7-9961-985eab69a315","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092036283140882552:744c3daf-b1dc-4b92-abfd-29a259042bca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092186411227050187:76e085ae-5a9c-451f-9b63-53f1485d7319","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092191757609967867:14e4007e-9249-4043-8462-5a449b041b7f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092205453744787954:f11885bf-cd3a-4952-aac4-0732342e6ffd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092280977766629489:49400ac5-60f3-40d7-a113-07c2a6adc533","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092290572576759871:2d36015e-d07f-4f24-880f-275164cba440","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092577317021208880:3c6f6501-52eb-470a-9b48-d3ab18c861be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093954797858639921:c4bf6672-5d06-4f10-9f31-88ceb57d246d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094455704845435292:8512ecdd-cfd8-4925-8ce2-29eafc12284e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094843389791342898:9d094c77-cb34-40d5-838c-889993303435","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095204804704555385:a61ce28e-92c4-4481-938f-accc184aaab2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095859432512966918:9ea7305b-7f24-4115-9c03-1afd902fe10f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096280697057218595:b9efb5c9-4f80-4f44-8071-f03f47649522","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096976794918502574:1254b396-798c-4329-bc13-8ed576720457","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098105537820811590:0a051ee7-f0dd-4e35-9b1e-dc86dc652681","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099891996223778930:55e92562-92a4-4301-bc5a-16c42ec8bd28","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110044333806321879:729c93d6-ddd1-4417-8074-23022a68de24","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110044688401174608:0daf88c5-0e82-40f7-80df-116f2fc0142d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112186568635207681:ae19f0f8-1c65-48b7-864e-68b4d6e3636e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112245552372920408:fc3132a8-61e5-486a-86b4-6843cc1ecf86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113648894789681559:236ebb0a-beae-4de0-aab3-55a207faa85f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:726670725441044480:9a61f2d7-19d1-4cfd-ba71-be805c49a486","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:731001983327330305:7a967b3c-c37a-459f-bcf5-b1f39cab018e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:743762458238554113:8c70a924-95f0-4ddd-a299-a7778f90ded5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:743778655638327296:409ec231-881d-49d7-aec2-aa704d85fe9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:751374615226777600:ef05dc36-b241-40f6-bcc9-3a3676962330","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:753486654774583296:8f9f1809-e8db-4543-8134-ac7102eff277","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:874943031463616512:320b34e3-2176-4a4d-bd37-ef5552025733","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:883311367041818624:ea9033e1-1d72-4df9-857a-eebc3cb0da1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:883412704203075585:945813ff-442e-442c-9d47-d1dcc565de5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:946695082513719296:3ced82ec-2c75-473e-bf7f-58be19e2bf3c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:946696019391275013:c61cd0ba-066d-4dd6-a70c-9ae9973ef8f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:947900511780528128:8995c879-0572-4e74-bca5-ed1ce5a1efaa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:948221674058584064:624a471c-5ec4-4de8-a2ca-610ccfb967b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:948682596455780354:44d9fc6d-29dc-4d4c-8e33-f4ed9f032827","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:950774681442897920:1f081c0a-d7bd-4367-9e37-be69d4d60089","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:953631396731523072:b1bae467-3c72-40af-8d5f-ee184b82b698","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:957979859027931139:6a49bc3f-553b-444f-a1e2-eef359eb7d53","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:960835323394772992:f895f5bf-0cf3-4dee-b258-3604efb11b6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:960928394106949632:9d50f968-62e7-4901-a466-4967fb4a8073","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:996809402505158657:ed3ed526-3d06-4959-b0dd-edd01e267010","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1531665392456060928","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1735691153213673783","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1919031367221772692","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2092024383543886075","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:W73XWDQAyLo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:f5mDSCI3wYc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":7,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":145,"x_video":4,"youtube":2},"by_evidence_role":{"commentary":160},"count":160,"evidence_window":{"end":"2026-10-29","start":"2016-05-01"},"retrieval_snapshot":"2026-10-31T10:05:32.343490Z","timeline":[{"count":1,"week":"2016-W17"},{"count":1,"week":"2016-W19"},{"count":2,"week":"2016-W24"},{"count":1,"week":"2016-W27"},{"count":1,"week":"2016-W28"},{"count":1,"week":"2017-W24"},{"count":2,"week":"2017-W27"},{"count":2,"week":"2017-W52"},{"count":3,"week":"2018-W01"},{"count":1,"week":"2018-W02"},{"count":1,"week":"2018-W03"},{"count":1,"week":"2018-W05"},{"count":2,"week":"2018-W06"},{"count":1,"week":"2018-W20"},{"count":1,"week":"2018-W27"},{"count":1,"week":"2018-W35"},{"count":1,"week":"2019-W17"},{"count":2,"week":"2019-W23"},{"count":1,"week":"2019-W27"},{"count":1,"week":"2019-W33"},{"count":1,"week":"2019-W41"},{"count":1,"week":"2019-W46"},{"count":1,"week":"2020-W03"},{"count":3,"week":"2020-W07"},{"count":1,"week":"2020-W08"},{"count":1,"week":"2020-W23"},{"count":3,"week":"2020-W50"},{"count":1,"week":"2021-W01"},{"count":1,"week":"2021-W02"},{"count":1,"week":"2021-W29"},{"count":1,"week":"2021-W30"},{"count":1,"week":"2021-W41"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2022-W05"},{"count":1,"week":"2022-W12"},{"count":3,"week":"2022-W14"},{"count":1,"week":"2022-W19"},{"count":1,"week":"2022-W20"},{"count":2,"week":"2022-W21"},{"count":4,"week":"2022-W22"},{"count":12,"week":"2022-W23"},{"count":1,"week":"2022-W25"},{"count":1,"week":"2022-W33"},{"count":1,"week":"2022-W38"},{"count":2,"week":"2022-W42"},{"count":1,"week":"2022-W44"},{"count":1,"week":"2023-W02"},{"count":2,"week":"2023-W03"},{"count":1,"week":"2023-W05"},{"count":2,"week":"2023-W06"},{"count":2,"week":"2023-W07"},{"count":1,"week":"2023-W10"},{"count":2,"week":"2023-W19"},{"count":1,"week":"2023-W45"},{"count":2,"week":"2023-W46"},{"count":2,"week":"2023-W50"},{"count":1,"week":"2024-W09"},{"count":2,"week":"2024-W17"},{"count":1,"week":"2024-W19"},{"count":1,"week":"2025-W17"},{"count":12,"week":"2025-W18"},{"count":4,"week":"2025-W19"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W28"},{"count":2,"week":"2025-W37"},{"count":1,"week":"2025-W48"},{"count":2,"week":"2026-W21"},{"count":28,"week":"2026-W35"},{"count":5,"week":"2026-W36"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":3,"week":"2026-W42"},{"count":4,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: long course concurrent chemoradiation with capecitabine and radiotherapy","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Adenocarcinoma of the Rectum","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"STAR-TREC","aliases":["STAR-TREC","Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?","STAR-TREC: Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?"],"brief_title":"Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Adenocarcinoma of the Rectum"],"display_condition":"early rectal cancer","display_interventions":[],"enrollment":{"count":380,"type":"ESTIMATED"},"interventions":[{"name":"Standard TME surgery","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"PROCEDURE"},{"name":"Long course concurrent chemoradiation with capecitabine and radiotherapy","synonyms":["Xeloda is the brand name for capecitabine"],"type":"DRUG"},{"name":"Short course radiotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"}],"nct_id":"NCT02945566","official_title":"STAR-TREC: Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2027-08","type":"ESTIMATED"},"primary_endpoints":[{"description":"Measured at 12 and 24 months. Target recruitment rates are ≥4 and ≥6 patients randomised per month at 12 and 24 months respectively for total accrual of 120 international cases. Each individual country will attempt to exceed the minimum recruitment required to sustain phase III (UK 75, the Netherlands 75, Denmark 30). If recruitment is on target in year two then consideration will be given to an early application for transition to phase III with a funding application and a formal protocol amendment.","measure":"Phase II (Feasibility study) Primary Outcome: Recruitment Rate","timeFrame":"24 Months"},{"description":"The primary endpoint of the STAR-TREC phase III study is the proportion of patients with successful organ preservation at 30 months from the start day of (chemo)radiotherapy treatment. This endpoint will be assessed for patients who prefer organ preservation and is defined as an in-situ rectum (includes patients subject to transanal local resection), no defunctioning stoma and an absence of active loco-regional cancer failure. The expected incidence of this outcome is approximately 60%.","measure":"Phase III Primary Outcome: Organ Preservation","timeFrame":"30 Months from start day of (chemo)radiotherapy treatment."}],"registered_date":{"date":"2016-10-26","type":"ESTIMATED"},"registry_last_updated":"2026-06-29","registry_url":"https://clinicaltrials.gov/study/NCT02945566","short_name":"STAR-TREC","short_name_basis":"registry_acronym","sponsor":"University of Birmingham","start_date":{"date":"2017-06-14","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2, phase3","study_ids":[{"id":"RG_15-011","type":"sponsor_study_id"},{"id":"2016-000862-49","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}